Skip to Content

Sapna Patel, B.A, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2005 The University of Texas Medical Branch, Galveston, TX, MD, Medicine
2000 The University of Texas at Austin, Austin, TX, BA, Microbiology

Postgraduate Training

7/2008-1/2011 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/2006-6/2008 Clinical Residency, Internal Medicine, The University of Colorado at Denver and Health Sciences Center, Denver, CO
6/2005-6/2006 Clinical Internship, Internal Medicine, The University of Colorado at Denver and Health Science Center, Denver, CO

Board Certifications

11/2011 American Board of Internal Medicine, Medical Oncology
8/2008 American Board of Internal Medicine


Administrative Appointments/Responsibilities

Uveal Melanoma Assembly, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2011-present
Fellowship Director of Moonlighting, Department of Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2010-1/2011

Other Appointments/Responsibilities

Editorial Board, OncoLog, Houston, TX, 7/2012-present
Clinical Specialist, Department of General Internal Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX, 11/2008-1/2011


Reviewer, The Medical Letter, New Rochelle, NY, 2011

Institutional Committee Activities

Member, Clinical Research Committee 3, 9/2011-8/2012

Honors and Awards

2010 Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, MD Anderson Cancer Center
2010 ASCO Cancer Foundation Merit Award, ASCO Annual Meeting
2010 ASCO Cancer Foundation Merit Award, ASCO-NCI-EORTC Molecular Markers in Cancer Annual Meeting
2009 Young Investigator Award, Ocular Melanoma Foundation
2006-2007 Finalist, Humanism andExcellence in Teaching, The University of Colorado at Denver and Health Sciences Center School of Medicine
2006 2nd Place, Rocky Mountain Hospitalist Symposium Abstract Competition
2006 2nd Place, Biosymposia Signaling Transduction Modulators in Cancer Therapy Symposium
1999 College of Natural Sciences Honor List, The University of Texas at Austin
1999 College Scholar, The University of Texas at Austin

Professional Memberships

American Association of Physicians of Indian Origin Medical Students, Residents and Fellows Section
Member, 8/2008-present
American Board of Internal Medicine
Diplomat, 8/2008-12/2018
American College of Physicians
Associate Member, 2006-2007
American Medical Association
MSS Hospitality Committee, Annual Meeting, 6/2004
MSS Committee On Long Range Planning, 2004-2005
Member, 2001-2008
American Society of Clinical Oncology
The Association for Research in vision and Ophthalmology Member, 11/2011-12/2012
Associate Member, 7/2009-present
European Society of Medical Oncology, United Kingdom
Member, 6/2012-present
Golden Key International Honor Society
Member, 1999-2000
International Rare Cancers Initiative
Member, 6/2012
Network of Indian Professionals
Member, 8/2008-present
Sigma XI Scientific Research Society
Member, 2010
Member, 1998-2007
Texas Medical Association
Member, 2008-2009
Member, 2001-2005

Selected Publications

Peer-Reviewed Original Research Articles

1. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther 14(4):847-856, 4/2015. e-Pub 2/2015. PMID: 25695955.
2. Osada T, Patel SP, Hammond SA, Osada K, Morse MA, Lyerly HK. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother. e-Pub 3/6/2015. PMID: 25742933.
3. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. J Invest Dermatol 135(2):508-15, 2/2015. e-Pub 8/22/2014. PMCID: PMC4289407.
4. Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu WJ, Bedikian AY, Davies MA, Woodman SE, Hwu P. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma. Melanoma Res 24(4):342-8, 8/2014. PMCID: PMC4278368.
5. Patel SP. It's Right, Left is Rare. Ann Thorac Surg 97(4):1482-3, 4/2014. PMID: 24694446.
6. Kim CY, Kim DW, Kim K, Curry J, Torres-Cabala C, Patel S. GNAQ mutation in a patient with metastatic mucosal melanoma. BMC Cancer 14:516, 2014. e-Pub 7/2014. PMCID: PMC4223398.
7. Kim DW, Patel SP. Profile of selumetinib and its potential in the treatment of melanoma. Onco Targets Ther 7:1631-9, 2014. e-Pub 9/19/2014. PMCID: PMC4179759.
8. Patel SP. Latest developments in the biology and management of uveal melanoma. Curr Oncol Rep 15(6):509-16, 12/2013. PMID: 24122445.
9. Kolandjian NA, Wei C, Patel SP, Richard JL, Dett T, Papadopoulos NE, Bedikian AY. Delayed Systemic Recurrence of Uveal Melanoma. Am J Clin Oncol 36(5):443-9, 10/2013. e-Pub 6/2012. PMID: 22706174.
10. Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. J Immunother 36(4):276-86, 5/2013. PMCID: PMC3799876.
11. Patel SP, Lazar AJ, Papadopoulos NE, Liu P, Infante JR, Glass MR, Vaughn CS, LoRusso PM, Cohen RB, Davies MA, Kim KB. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer 119(4):799-805, 2/15/2013. e-Pub 9/12/2012. PMID: 22972589.
12. Francis JH, Patel SP, Gombos DS, Carvajal RD. Surveillance options for patients with uveal melanoma following definitive management. Am Soc Clin Oncol Educ Book:382-7, 2013. PMID: 23714555.
13. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758-70, 12/15/2012. e-Pub 10/2/2012. PMCID: PMC3525747.
14. Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol 39(9):821-5, 9/2012. e-Pub 7/19/2012. PMCID: PMC3881367.
15. Alvarado G, Noor R, Bassett R, Papadopoulos NE, Kim KB, Hwu WJ, Bedikian A, Patel S, Hwu P, Davies MA. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res 22(4):310-5, 8/2012. e-Pub 5/2012. PMCID: PMC4105847.
16. Patel SP, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P, Prieto VG, Bar-Eli M, Zigler M, Dobroff A, Bronstein Y, Bassett RL, Vardeleon AG, Bedikian AY. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res 21(4):357-63, 8/2011. PMCID: PMC3132394.
17. Kolandjian NA, Patel SP, Papadopoulos NE, Bedikian AY. The left ventricle as the first site of uveal melanoma metastasis 13 years after treatment of the primary tumor. Melanoma Res 21(2):160-3, 4/2011. PMID: 21346640.

Invited Articles

1. Patel SP, Kim KB. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. Expert Opin Investig Drugs 21(4):531-9, 4/2012. e-Pub 3/7/2012. PMID: 22394161.
2. Patel SP, Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther 2011(5):489-495, 2011. e-Pub 12/16/2011. PMCID: PMC3257959.
3. Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 8(4):493-9, 7/2009. PMID: 19435405.


1. Patel SP, Bedikian AY, Hwu WJ, Kim KB, Homsi J, Davies MA, Woodman SE, Radvanyi L, Woodard K, Mahoney SL, Hwu P. Ipilimumab plus temozolomide in metastatic melanoma, 6/2011.
2. Patel SP, Lazar AJ, Mahoney S, Vaughn C, Gonzalez N, Papadopoulous NE, Liu P, Infante JR, LoRusso PM, Kim KB. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutation in patients with metastatic melanoma, 10/2010.
3. Patel S, Bedikian A, Papadopoulos N, Hwu P, Vardeleon A, Prieto V, Bar-Eli M, Bronstein Y, Bassett R, Kim K. A Phase II Study of Gefitnib (IRESSA) in Patients with Metastatic Melanoma, 6/2009.

Book Chapters

1. Chae YK, Patel SP, Kim KB. Emerging Targets for Melanoma Therapy Besides BRAF. In: Emerging Cancer Theraputics: Melanoma. Demos Medical Publishing LLC: New York, NY, 2012.
2. Joseph RW, Kim K, Patel SP. Ch. 27: Role of Chemotherapy, biochemotherapy, and targeted systemic therapies in the treatment of melanoma. In: Cutaneous Malignancy of the Head and Neck: A Multidisciplinary Approach. Plural Publishing: San Diego, CA, 2011.
3. Patel SP, Buzdar AU. Ch.24: Early and locally advanced breast cancer. In: M. D. Anderson Manual of Medical Oncology 2nd ed. McGraw-Hill: New York, 2011.


1. Blog. SP Patel, Uveal Melanoma: What is it? Cancerwise blog. 12/01/2011,
2. Blog. SP Patel, Treating Uveal Melanoma. Cancerwise blog. 01/18/2012,

Grant & Contract Support

Title: High-dose interleukin-2 video series
Funding Source: Volunteer Endowment for Patient Support (VEPS)
Role: Project Leader
Duration: 4/27/2012

Last updated: 12/18/2015